THC vs CBD: The Definitive Cannabinoid Guide

Tetrahydrocannabinol (THC) is the primary psychoactive cannabinoid in cannabis. THC binds primarily to CB1 receptors concentrated in the central nervous system, particularly in the hippocampus, basal ganglia, cerebellum, and cortex. The CB1 binding produces the characteristic cannabis high: altered perception of time, mild visual and auditory enhancement, appetite stimulation ("the munchies"), mood elevation, physical relaxation, and the cognitive shift that consumers describe as feeling stoned.

THC also produces secondary effects mediated by other receptors and downstream pathways. Anti-nausea action makes THC and its synthetic analog (Marinol/dronabinol) clinically useful for chemotherapy patients. Pain modulation through both CB1 binding and indirect mechanisms makes THC useful for chronic pain in some patients. Sleep induction at higher doses makes THC useful for some sleep applications. Creative-task performance enhancement at moderate doses is reported by some individuals, though the research is mixed.

Side effects at higher doses include increased heart rate, dry mouth, dry eyes, short-term memory impairment, paranoia or anxiety in sensitive individuals, and impaired motor coordination. These effects are dose-dependent, individual-variable, and time-limited; they resolve as the THC clears the system. The dose that produces a comfortable experience for a regular consumer can produce significant paranoia in an inexperienced consumer, which is why dose calibration matters.

THC is the cannabinoid that NYS-licensed cannabis is taxed on (the state excise rate is 9 percent of total THC content, layered with the 4 percent local excise and the standard sales tax). The THC percentage on the label is the primary potency indicator at the dispensary.

Cannabidiol (CBD) is non-psychoactive at typical adult-use doses. CBD does not bind strongly to CB1 receptors. Instead, CBD modulates the endocannabinoid system through several indirect mechanisms.

Weak CB1 antagonism. When taken together with THC, CBD partially blocks THC's CB1 binding, reducing the psychoactive intensity. This is the pharmacology behind "balanced" or "1:1" products that combine both cannabinoids.

CB2 receptor binding. CBD binds to CB2 receptors in the immune system and peripheral tissues, which mediates much of the anti-inflammatory action attributed to CBD.

Serotonin 5-HT1A modulation. CBD interacts with serotonin receptors involved in anxiety and mood regulation. This is one of the proposed mechanisms behind CBD's anxiety-reducing effect.

Anandamide enzyme inhibition. CBD inhibits the FAAH enzyme that breaks down anandamide, the body's own endocannabinoid. The result is elevated levels of the body's natural endocannabinoid signal.

CBD's primary effects include anxiety reduction (the strongest research base), anti-inflammatory action, anticonvulsant effect (FDA-approved for specific seizure disorders as Epidiolex since 2018), pain modulation, and sleep support without psychoactive intoxication.

CBD also reduces THC's intensity when taken together, as noted above. A 1:1 CBD:THC product produces a less intense psychoactive experience than a THC-only product at the same THC dose. The CBD does not "cancel" the THC, but it does buffer the intensity in a clinically measurable way.

The endocannabinoid system (ECS) is a regulatory network discovered in the late 1980s and early 1990s as researchers worked backward from cannabis pharmacology to identify the receptors and endogenous compounds. The ECS includes two primary receptor types, plus the body's own cannabinoid-like compounds and the enzymes that produce and degrade them.

CB1 receptors. Concentrated in the brain and central nervous system, with high density in regions governing memory, perception, motor control, appetite, and mood. THC binds here directly, producing psychoactive effects. CB1 is one of the most abundant G-protein-coupled receptors in the brain.

CB2 receptors. Concentrated in the immune system and peripheral tissues. CBD binds here. CB2 binding mediates immune-modulating, anti-inflammatory effects.

Endogenous cannabinoids (endocannabinoids). The body produces its own endocannabinoid compounds, primarily anandamide and 2-arachidonoylglycerol (2-AG), that bind to CB1 and CB2 receptors as part of normal physiological regulation. Plant-based cannabinoids from cannabis (THC, CBD, CBG, CBN) interact with the same receptors that the body's endogenous compounds use.

Regulatory function. The ECS is involved in regulating sleep, mood, appetite, immune function, pain perception, memory, and stress response. It operates as a homeostatic feedback system, fine-tuning other neurotransmitter systems rather than producing direct signals.

Cannabis works because plant cannabinoids interact with a regulatory system that already exists in the human body. This is part of why cannabis effects vary so much across individuals: the underlying endocannabinoid tone, receptor density, and enzyme activity vary, which produces different responses to identical doses.

THC-dominant (10:1 THC:CBD or higher, or pure THC). Standard adult-use cannabis. Use for psychoactive recreational experiences, evening wind-down, sleep induction at higher doses, social enhancement, creative work, appetite stimulation. The bulk of the NYS adult-use market falls in this category. Most flower, pre-rolls, vape cartridges, edibles, and concentrates are THC-dominant.

Balanced 1:1 CBD:THC. Reduced psychoactive intensity compared to THC-dominant. Use for anxiety management with mild psychoactive effect, daytime social use with reduced intensity, pain management without strong high, and learning the body's response without committing to full-intensity THC. A useful starting ratio for first-time consumers. Available in tinctures, edibles, and some pre-rolls and flower in the NYS market.

2:1 or higher CBD:THC. Significantly reduced psychoactive effect. Use for anxiety, mild pain, sleep support without strong high, daytime functional use, and customers who want the entourage effect of THC plus CBD without much intoxication. Tincture format is most common.

CBD-dominant (10:1 CBD:THC or higher, or pure CBD). Non-psychoactive. Use for anxiety management without intoxication, anti-inflammatory action, pain management without high, sleep support without psychoactive effect, and customers who want the cannabinoid benefits without any cannabis high. Tinctures, capsules, and topicals are the common formats.

The choice between ratios is one of the most useful conversations at the counter. A customer who has a bad past experience with high-THC cannabis is often well-served by a 2:1 or 1:1 product on their next visit, rather than abandoning cannabis entirely. A customer who finds pure CBD ineffective for their target use case is sometimes well-served by adding a small THC component (1:4 or 1:2 THC:CBD) for the entourage effect.

NYS-licensed cannabis products display cannabinoid content on the package per OCM Part 113 regulation. The standard label shows.

Total THC percentage. Combines THC and THC-A converted at decarboxylation under heat. THC-A is the precursor form found in unheated cannabis; THC-A becomes THC when the cannabis is smoked, vaped, or baked into an edible. The label calculation accounts for this conversion.

Total CBD percentage. Combines CBD and CBD-A similarly.

Per-serving cannabinoid content. For edibles, beverages, and tinctures, the label shows milligrams of THC and CBD per serving and per package. NYS edibles are capped at 10 mg per serving and 100 mg per package.

Other detected cannabinoids. CBG, CBN, CBC, THCV at lower percentages if present.

Terpene profile. Often included on the label or on the linked COA.

The QR code on every NYS-licensed package links to the full Certificate of Analysis from NYS-certified third-party laboratory testing. The COA is the empirical answer to any cannabinoid question; the label is the at-a-glance summary.

CBG (cannabigerol). The "mother cannabinoid" because other cannabinoids derive from CBG-A during plant development. CBG appears at low percentages (1 to 3 percent) in mature flower as most CBG-A converts to THC-A or CBD-A during ripening. Reported effects include focus, mood elevation, and anti-inflammatory action. Higher-CBG cultivars and CBG-isolated products are increasingly available in NYS dispensaries, often marketed for daytime functional use.

CBN (cannabinol). Forms as THC degrades, particularly through heat and air exposure. Aged cannabis or cannabis that has been heated repeatedly develops higher CBN content. Reported effects include sedation and sleep support. Often marketed as a sleep aid in tincture, edible, and gummy formats. The sleep claim has some research support but is less established than the basic CBD anxiety research.

CBC (cannabichromene). Minor cannabinoid with anti-inflammatory and analgesic properties. Appears at low percentages in most cultivars. Increasingly featured in full-spectrum products marketed for the entourage effect.

THCV (tetrahydrocannabivarin). Minor cannabinoid with appetite-suppressant effect (unlike THC, which stimulates appetite). Higher in some African landrace sativa cultivars including some Durban Poison phenos. Marketed for daytime functional use and weight-management adjacent positioning, though clinical research is early.

Delta-8 THC. Isomer of delta-9 THC with reduced psychoactive intensity. Mostly sold in the hemp-derived market under the federal Farm Bill rather than in NYS-licensed adult-use dispensaries. The hemp-derived delta-8 market has had quality and safety concerns; NYS-licensed adult-use cannabis is the more reliable path for any THC product.

A useful sequence for picking the right ratio.

Step 1: What is the target effect? Recreational high, anxiety reduction, sleep support, pain management, focus, social use, creative work, exercise warm-up, no-high functional use.

Step 2: What is your prior cannabis experience? Never, casual, regular, daily. Calibrate dose and ratio against tolerance.

Step 3: Any specific sensitivities? Past anxiety from cannabis, paranoia from past use, racing-heart sensitivity, low alcohol tolerance (a rough proxy for cannabinoid sensitivity).

Step 4: Format preference? Inhaled (flower, vape, concentrate) for fast onset, edible/beverage for longer duration, tincture/topical for low-dose precision.

The budtender then matches a product to those four answers. A first-time customer with a sleep target and a no-prior-experience profile typically gets a 1:1 or 2:1 tincture or low-dose edible recommendation, not a high-THC flower jar.

Will CBD get me high?

No. CBD at typical doses is non-psychoactive. CBD does not bind strongly to CB1 receptors in the brain. Some people report subtle effects like reduced anxiety, mild relaxation, or improved mood, but not the characteristic cannabis "high." Pure CBD products are an option for consumers who want cannabinoid effects without intoxication.

Will THC and CBD together produce a stronger high?

No, the opposite. CBD partially blocks THC's CB1 binding when taken together, which reduces the psychoactive intensity. A 1:1 product produces a less intense high than a pure THC product at the same THC dose. The CBD does not cancel the THC; it buffers it in a clinically measurable way.

Is CBD legal in NYC?

Yes. CBD derived from hemp (under 0.3 percent THC) is federally legal under the 2018 Farm Bill and broadly available in NYC. CBD derived from cannabis (over 0.3 percent THC) is legal in NYC under NYS adult-use law for adults 21 and over. NYS-licensed dispensaries sell cannabis-derived CBD products in tincture, edible, topical, and flower formats.

Is THC legal in NYC?

Yes. Adult-use cannabis containing THC is legal in NYC for adults 21 and over under MRTA (March 2021) and OCM regulation. Federal law still prohibits cannabis, but the federal-versus-state conflict does not affect day-to-day retail operation at NYS-licensed dispensaries.

What is the right CBD:THC ratio for first-time users?

Start with a 1:1 balanced product or a 2:1 CBD-leaning product. The CBD buffers the THC effect and produces a more manageable first experience. Low total dose matters too: a 1:1 product at 2.5 mg THC per serving is the gentler start. Increase THC dominance only after confirming response across two or three sessions.

Can THC and CBD show up on a drug test?

Yes, both can show up on cannabis drug tests. THC tests most commonly because the standard urine drug test panels detect THC metabolites (THC-COOH). CBD products that contain trace THC, which most legal CBD products do, can produce positive cannabis tests. See /faq/cannabis-drug-testing/ for the full drug testing breakdown.

What is the entourage effect?

The entourage effect is the proposed pharmacological phenomenon where cannabinoids and terpenes work together to produce effects different from any single compound alone. Full-spectrum products (containing THC, CBD, minor cannabinoids, and the cultivar's native terpene profile) are marketed on this theory. The research support is mixed but growing.

Does smoking THC versus eating THC produce different effects?

Yes. Smoked THC produces a fast onset (2 to 5 minutes), shorter duration (2 to 4 hours), and a different metabolite profile. Edible THC produces a slower onset (60 to 90 minutes), longer duration (4 to 8 hours), and is converted in the liver to 11-hydroxy-THC, a metabolite that crosses the blood-brain barrier more readily and produces a more intense body-forward effect at the same nominal dose.

Where can I learn more about specific cannabinoid products?

The Alchemy carries cannabis-derived CBD products and THC products across all ratios at both Chelsea and Flatiron. The budtender can walk through the cannabinoid content of any product on the shelf and pull the COA. The tincture category at /tinctures/ has the broadest ratio variety; the edibles category at /edibles/ includes 1:1 and 2:1 options alongside the standard THC-dominant gummies.

Is CBG worth seeking out as a primary cannabinoid?

CBG is an interesting minor cannabinoid with early research support for focus, mood, and anti-inflammatory action. CBG-dominant products are available in NYS dispensaries in limited supply. Worth trying if the use case is daytime functional support; not a replacement for CBD where the anxiety research base is more established.